Harmine Plus Exendin-4 Enhances Remission of Recent-Onset Type 1 Diabetes Following Anti-CD3 Therapy
Geming Lu, RANDY KANG, MIGUEL VARELA, Eunjin Oh, Yansui Li, Jungeun Lee, Leah Kebrom, Juan Aldaco, Jiamin Zhang, Madeline Wichman, Mingpei Li, FOUAD R. KANDEEL, Meirigeng Qi, Peng Wang, Robert J. DeVita, , Adolfo Garcı́a-Ocaña
This study shows that harmine plus exendin-4, when combined with anti-CD3 therapy, promotes beta-cell recovery and reduces immunogenicity, leading to remission of recent-onset type 1 diabetes.
bioRxiv · Sep 22, 2026 · PreprintCell Biology